Fact Sheet

The Cost of 340B to **Delaware**

In 2025, workers and employers lost $39 million in negotiated rebates to 340B

Despite advocates' claims that the 340B program is free, it raises costs for patients, employers, state and local governments, Medicare, and managed Medicaid. One way it increases costs is by displacing the negotiated rebates that are used to lower net drug prices. Research by IQVIA shows that workers and employers lost $14.5 billion in rebates nationally in 2025 due to 340B.[1] The cost to Delaware workers and employers in 2025 was $39 million.

Cost of 340B to Delaware workers and employers

PER BENEFICIARY	PLAN TYPE	TOTAL COST
$73	Private sector employees[2]	**$34M**
	Government employees[3]	**$5M**
	Total	**$39M**

340B also displaces rebates in managed Medicaid, which cost the state of Delaware $8M in 2025.

Cost of 340B to Delaware managed medicaid

PER BENEFICIARY	STATE'S TOTAL COST
$42	**$8M**

From 2023 to 2025, both the number of healthcare providers prescribing 340B drugs and the number of 340B facilities increased while the value of 340B drug purchases decreased.

340B growth in Delaware: 2023 to 2025

340B PRESCRIBERS		340B FACILITIES[4]		340B DRUG PURCHASES[5]	
#	GROWTH	#	GROWTH	#	GROWTH
41,740	+68%	1,494	+70%	$531 million	-29%

340B utilization varies markedly across Delaware and neighboring states, underscoring that the program's financial burden is not borne uniformly.

Delaware vs. neighbors

STATE	340B UTILIZATION[6]	COST PER BENEFICIARY
DE	13%	$73
PA	14%	$82
NJ	4%	$25
MD	8%	$48
Total U.S.	**14%**	**$81**

1. The cost of 340B to states. IQVIA. 2026 (to appear).
2. Includes employer-sponsored plans and ACA health plans.
3. Includes state and local government employees.
4. Based on 340B "parent" facilities, not satellite sites or contract pharmacies.
5. 340B drug purchases at Wholesaler Acquisition Cost (WAC).
6. Percentage of 340B business by state, averaged over drug purchases and claims.

CONTACT US

iqvia.com

©2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. 07.2026.US. 26-CRS-2197-06JUN